This Breakthrough Twice-Yearly Injection Shows 96% Efficacy Against HIV
Gilead Sciences’ lenacapavir, a biannual injection for PrEP, has been hailed as a breakthrough in HIV prevention after results from a new study showed a 96% reduction in HIV infections. Gilead plans to submit lenacapavir for regulatory approvals by the end …